Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:05 PM
Ignite Modification Date:
2025-12-24 @ 11:05 PM
NCT ID:
NCT07250269
Eligibility Criteria:
Inclusion Criteria:
1. Confirmed histopathological diagnosis of AL amyloidosis
2. One or more organs currently or historically impacted by AL amyloidosis according to consensus guidelines
3. Measurable hematologic disease: dFLC \> 20 mg/L or serum M-protein \> 5g/L
4. Relapsed disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
5. ECOG performance status of 0 to 1
6. Must be able and willing to adhere to the study visit schedule and other protocol requirements
7. Women of child-bearing potential (WCBP) must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.
Exclusion Criteria:
1. Have any other form of amyloidosis other than AL amyloidosis
2. Mayo Stage IIIb AL amyloidosis
3. Oxygen saturation \< 95% on room air
4. Systolic blood pressure \<100mmHg
5. Cardiac exclusion criteria:
1. Mayo Stage IIIb AL amyloidosis (Wechalekar, 2013)
2. NT-proBNP levels as follows:
NT-proBNP ≥ 2000 ng/L (for dose escalation portion) NT-proBNP \< 2000 and \> 5000 ng/L (for dose extension portion) c. High-sensitivity cardiac troponin T \> 75 ng/L d. NYHA class III or IV 5. Extensive GI involvement with evidence of active GI bleeding/risk of bleeding as determined by Investigator 6. Prior therapies:
1. CAR T cell therapy directed at any target
2. Prior BCMA-targeting therapy
3. Prior treatment with any approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.
7\. Toxicity from previous anti-cancer or anti-PC-directed therapy did not resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
8\. Active plasma cell leukemia at the time of screening 9. Multiple myeloma defined as clonal bone marrow PCs ≥10% and any one or more of the following myeloma defining events (deemed as attributable to multiple myeloma by Investigator) (Rajkumar, 2014) 10. Seropositive for HIV 11. Serologic status reflecting active hepatitis B or C:
1. Positive HBsAg, or
2. Patients with positive core antibody (anti-HBc) and HBV-DNA positive.
3. Patients with positive hepatitis C antibody and HCV RNA positive.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07250269
Study Brief:
Protocol Section:
NCT07250269